Previous 10 | Next 10 |
Targeting a market that could reach $1.1 trillion by 2050, Cortexyme ( CRTX ) will probably interest institutional investors. Besides, the company appears to have sufficient equity financing to complete its Phase 2-3 clinical trial. In addition, the fact that Pfizer ( PFE ) is among the shareh...
Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m...
Gainers: PHAS +31.6% . GWPH +4.1% . RUHN +2.9% . IGC +1.9% . SENS +1.9% . More news on: PhaseBio Pharmaceuticals, Inc., GW Pharmaceuticals plc, Hangzhou Ruhnn Holding Co.,Ltd, Stocks on the move, Read more ...
Leerink's Geoffrey Porges likes the upside of arthritis med filgotinib for Gilead Sciences (NASDAQ: GILD ), projecting a $5 - 6/share potential bump in value. He says the JAK1 inhibitor has an 80% (unclear how he arrived at this specific figure) chance of reaching $3.7B in peak sales (how fa...
(Rendition of Brain Neurons, Source: NIH) The biotech sector has continued to participate in the market rally. One of the reasons is the strength in biopharma M&A activity, which provides unique support for valuations and particularly assists the small-and-midcap biotech companies. We ...
SOUTH SAN FRANCISCO, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the fourth quarter and full year ended...
Dosing is underway in a Phase 1b clinical trial evaluating Denali Therapeutics' (NASDAQ: DNLI ) DNL747 in Alzheimer's disease patients. The primary objectives are safety and biomarker data which will inform future studies. More news on: Denali Therapeutics, Inc., Sanofi, Healthcare st...
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced initiation of dosing in a Phase 1b clinical study of...
Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an...
Eiger BioPharmaceuticals (NASDAQ: EIGR ) initiated with Outperform rating and $47 (244% upside) price target at Baird. Shares up 13% premarket. More news on: Eiger BioPharmaceuticals, Inc., Vericel Corporation, Denali Therapeutics, Inc., Healthcare stocks news, Stocks on the mo...
News, Short Squeeze, Breakout and More Instantly...
Denali Therapeutics Inc. Company Name:
DNLI Stock Symbol:
NASDAQ Market:
Denali Therapeutics Inc. Website:
2024-05-10 10:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
U.S. stocks were mixed, with the Dow Jones gaining around 70 points on Wednesday. Shares of Louisiana-Pacific Corporation (NYSE:LPX) rose sharply d...
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal sto...